6/7/2023 Flashcards

1
Q

Lotensin

A

Benazepril

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Benazepril MOA

A

Prevents angiotensin I from being converted to angiotensin II by competitive inhibition, therefore preventing vasoconstriction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Benazepril class

A

ACE inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Cogentin

A

Benztropine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Benztropine MOA

A

Anticholinergic and antihistaminic effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Benztropine class

A

Anti-Parkinson agent, anticholinergic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Avastin

A

Bevacizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Bevacizumab MOA

A

Inhibits VEGF signaling pathways, therefore preventing vascular proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bevacizumab class

A

Antineoplastic, VEGF inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Lumigan

A

Bimatoprost

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bimatoprost MOA

A

Synthetic analog of prostaglandin; decreases intraocular pressure by increasing outflow of aqueous humor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bimatoprost class

A

Prostaglandin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Velcade

A

Bortezomib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Bortezomib MOA

A

Reversibly inhibits chymotrypsin-like activity at the 26S proteasome, leading to activation of signaling cascades, cell cycle arrest, and apoptosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bortezomib class

A

Antineoplastic, proteasome inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Lumify

A

Brimonidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Brimonidine MOA

A

Alpha-2 adrenergic agonist; causes reduction of aqueous humor formation and increased uveoscleral outflow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Brimonidine class

A

Alpha-2 adrenergic agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Suboxone

A

Buprenorphine/Naloxone

20
Q

Buprenorphine/Naloxone MOA

A

Buprenorphine - exerts analgesic effect via high affinity binding receptors in the CNS; partial mu agonist and weak kappa antagonist

Naloxone - opioid antagonist that competes with and displaces opioids at opioid receptor sites

21
Q

Buprenorphine/Naloxone class

A

Opioid analgesic/opioid partial agonist

22
Q

Zyban

A

Bupropion

23
Q

Wellbutrin

A

Bupropion

24
Q

Bupropion MOA

A

Inhibits neuronal uptake of norepinephrine and dopamine

25
Q

Bupropion class

A

Dopamine/norepinephrine reuptake inhibitor, antidepressant

26
Q

Buspirone MOA

A

high affinity for serotonin receptors; moderate affinity for dopamine D2 receptors

27
Q

Buspirone class

A

Miscellaneous antianxiety agent

28
Q

Jevtana

A

Cabazitaxel

29
Q

Cabazitaxel MOA

A

Microtubule inhibitor; binds to tubulin, promoting assembly into microtubules and inhibiting their disassembly and stopping the cell cycle

30
Q

Cabazitaxel class

A

Antimicrotubular antineoplastic agent; taxane derivative

31
Q

Caffeine MOA

A

Increases levels of 3’5’ cAMP by inhibiting phosphodiesterase. CNS stimulant, which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction

32
Q

Caffeine class

A

CNS stimulant; phosphodiesterase inhibitor

33
Q

Cannabidiol MOA

A

unknonwn

34
Q

Cannabidiol class

A

Cannabinoid; antiseizure agent

35
Q

Capsaicin MOA

A

Agonist for transient receptor potential vanilloid 1 receptor (TRPV1), an ion channel receptor complex expressed on nociceptive nerve fibers in the skin. Causes initial stimulation of TRPV1-expressing cutaneous nociceptors that may cause painful sensations, followed by pain relief caused by downregulation of TRPV1-expressing nociceptive nerve endings.

36
Q

Capsaicin class

A

Topical analgesic; TRPV1 agonist

37
Q

Tegretol

A

Carbamazepine

38
Q

Carbamazepine MOA

A

Decreases temporal stimulation leading to neural discharge by limiting influx of sodium ions across the cell membrane

39
Q

Carbamazepine class

A

Antizeisure agent

40
Q

Sinemet

A

Carbidopa/levodopa

41
Q

Carbidopa/levodopa MOA

A
42
Q

Carbidopa/levodopa class

A

Anti-parkinson agent

43
Q

Rytary

A

Carbidopa/levodopa

44
Q

Duopa

A

Carbidopa/levodopa

45
Q

Carbidopa/levodopa MOA

A

Levodopa crosses the BBB where it is converted to dopamine

Carbidopa inhibits peripheral breakdown of levodopa by inhibiting its decarboxylation, thereby increasing available levodopa at the BBB